

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

SYSMEX Corp. and SYSMEX
AMERICA, Inc.,

Plaintiffs,

v.

BECKMAN COULTER, Inc.,

Defendant.

Civil Action No. 19-1642-GBW

MEMORANDUM ORDER

Plaintiffs Sysmex Corp. and Sysmex America, Inc. (“Sysmex”) move to strike Defendant Beckman Coulter, Inc.’s (“Beckman”) written description defenses (D.I. 576) for the terms “plurality of detectors” and “the body fluid measuring mode includes a sequence of operations for measuring cells in the body fluid sample” (the “BFMM term”). D.I. 577 at 1. Since Beckman never asserted a lack of written description for these terms in either its expert report, D.I. 577-1, Ex. 2, or its invalidity contentions, D.I. 586-1, Ex. A, Ex. B, & Ex. C, the Court finds Beckman’s written description defenses untimely and will grant the Motion to Strike. The Court has reviewed the parties’ briefing, D.I. 577; D.I. 586; D.I. 587, and no hearing is necessary.

Claim 1 of United States Patent No. 10,401,350 (the “350 patent”) and of United States Patent No. 10,401,351 (the “351 patent”) recites:

A sample analyzer comprising:
a plurality of detectors each configured to sense cells in a sample . . . ;
a controller programmed to selectively operate the sample analyzer in a blood measuring mode or a body fluid measuring mode, wherein . . . **the body fluid measuring mode includes a sequence of operations for measuring cells in the body fluid sample**

D.I. 1-1, Ex. A at claim 1 & Ex. B at claim 1 (emphases added); *see also* D.I. 541 ¶ 15 (including claim 1 of the '350 and '351 patents among the “Asserted Claims”). The '350 and '351 patents share a common specification.¹ D.I. 1-1, Ex. A at 2 & Ex. B at 2 (explaining that both patents are continuations of United States Patent No. 8,968,661); *see also Wi-LAN USA, Inc. v. Ericsson, Inc.*, 675 F. App'x 984, 987 n.2 (Fed. Cir. 2017) (explaining that two patents “share a common specification” because one patent is a continuation of the other patent). Beckman contends that each patent’s claim 1—among other claims—are invalid for lack of written description. The Patent Act requires that each patent’s specification “contain a written description of the invention, and of the manner and process of making and using it” 35 U.S.C. § 112(a). “[A] patent’s specification must reasonably convey to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.” *Novartis Pharms. Corp. v. Accord Healthcare, Inc.*, 38 F.4th 1013, 1016 (Fed. Cir. 2022) (cleaned up).

Federal Rule of Civil Procedure 37(c)(1) provides that, “[i]f a party fails to provide information . . . as required by Rule 26(a) or (e), the party is not allowed to use that information . . . to supply evidence . . . at a trial, unless the failure was substantially justified or is harmless.” Beckman’s invalidity contentions are disclosures subject to Rule 26(a).² This Court has applied the so-called *Pennypack* factors to “determine whether a failure to make timely disclosure of

¹ “Strictly speaking, the specification includes both the written description and the claims. In common parlance, however, ‘specification’ is used to refer only to the written description component of a patent.” Tun-Jen Chiang & Lawrence B. Solum, *The Interpretation-Construction Distinction in Patent Law*, 123 Yale L.J. 530, 538, n.17 (2013). Here, the '350 and '531 patents share a common written description, but have different claims.

² *See Intell. Ventures I LLC v. AT&T Mobility LLC*, 2017 WL 658469, at *1 (D. Del. Feb. 14, 2017) (applying Rule 26(a) to initial infringement contentions); D.I. 29 ¶ 1 (incorporating “the Court’s Default Standard for Discovery”); *Default Standard for Discovery, Including Discovery of Electronically Stored Information*, U.S. Dist. Ct. for Dist. of Del., at 4–5 (Accessed Oct. 11, 2022), https://www.ded.uscourts.gov/sites/ded/files/pages/Electronic%20Discovery%20Default%20Standard_0.pdf (requiring initial invalidity and infringement contentions).

information required to be disclosed by court order or rule should lead to sanctions or should be regarded as harmless.” *Lipocine Inc. v. Clarus Therapeutics, Inc.*, 2020 WL 4794576, at *9 n.4 (D. Del. Aug. 18, 2020); *see id.* (declining to apply the *Pennypack* factors because the disclosure of “final invalidity contentions was not untimely”). The *Pennypack* factors are as follows:

(1) the prejudice or surprise in fact of the party against whom the evidence would have been presented, (2) the ability of that party to cure the prejudice, (3) the extent to which the presentation of the evidence would disrupt the orderly and efficient trial of the case or other cases in the court, (4) bad faith or willfulness in failing to comply with the court’s order, and (5) the importance of the excluded evidence.

LabMD Inc. v. Boback, 47 F.4th 164, 189 (3d Cir. 2022).

The Court’s Amended Scheduling Order, entered on October 15, 2021, provides that, “by no later than October 29, 2021, [Beckman] shall narrow its prior art invalidity positions to no more than 20 total prior art references and no more than 70 prior art invalidity grounds.” D.I. 373 ¶ 23 (emphasis omitted). That date was later amended to June 17, 2022. D.I. 553 at 2. In a June 10, 2022 letter, Sysmex argued that “[Beckman] refused to agree that it will identify the invalidity defenses it will assert at trial by June 17, 2022” and asked the court to “require [Beckman]’s narrowed defenses . . . to include . . . the specific limitations that form the basis of any § 112 defenses.” *Id.* Beckman responded that it would narrow its invalidity defenses but that the Court should reject Sysmex’s request for “a brand new . . . identification of ‘specific limitations’” because “Section 112 is not addressed in that way.” *Id.* Beckman contended that these “new narrowing requirements . . . were not negotiated, agreed upon, or even required under the applicable precedent.” *Id.* On June 14, 2022, the Court ordered Beckman “to identify the specific claim limitations that form the basis for its Section 112 defenses.” D.I. 561 at 1.

On June 17, 2022, Beckman disclosed that one of its defenses was

[i]nvalidity under § 112 for lack of written description for all asserted claims and claim 7 of the ‘351 patent, for the terms “multimode detectors,” “**plurality of**

detectors,” “electrical detector” and/or “the body fluid measuring mode includes a sequence of operations for measuring cells in the body fluid sample”, to the extent Plaintiffs contend those terms cover an electrical detector that is used to count white blood cells in the body fluid mode

D.I. 577-1, Ex. 1 at 1 (emphases altered). The parties’ dispute centers on only two of these terms:

(1) the “plurality of detectors” term and (2) the BFMM term.

Systemex argues that “[Beckman] disclosed for the first time on Friday, June 17, 2022 at 8:43 P.M. EST, that it was asserting written description defenses with respect to” the two terms at issue. D.I. 577 at 1. Systemex asserts that Beckman’s final expert report and Beckman’s final invalidity contentions both disclosed written description defenses for certain claim terms but failed to address either the “plurality of detectors” or the BFMM terms. *Id.* Thus, Systemex argues, the Court should strike these “new” invalidity defenses both for untimeliness and under the Third Circuit’s *Pennypack* test. *Id.* at 1–2. Beckman does not deny that its prior invalidity contentions or expert reports failed to discuss written description defenses for the two terms at issue. D.I. 586. Beckman instead argues that “whether the scope of the claim is supported by the specification . . . is independent of any specific limitation” because, here, “it is the *absence* of a limitation that establishes a lack of written description.” *Id.* at 2 (emphasis in original). Beckman argues that the claims asserted in this case “*lack[]* a limitation to optically counting white blood cells in body fluids” and, instead, “broadly cover *electrically* sensing and differentiating white blood cells in body fluids” when “the specification discloses only *optically* sensing such cells.” *Id.* at 1–2 (emphases in original). Systemex responds that Beckman never disclosed that its “written description defense is independent of any specific [claim] limitation” and that, to this point, “[Beckman]’s defenses have all been directed to specific claim limitations.” D.I. 587 at 1–2 (internal quotation marks and citations omitted).

First, the Court first finds that Beckman untimely disclosed its invalidity contentions as to the “plurality of detectors” term and as to the BFMM term. Beckman has argued, since at least May 7, 2020, that the “common patent specification . . . consistently discloses that an optical detector . . . is required to perform sensing of white blood cells in the body fluid” D.I. 586-1, Ex. A at 9, Ex. B at 13, & Ex. C at 13. Indeed, the Federal Circuit has recognized the validity of a similar argument. *ICU Medical, Inc. v. Alaris Medical Systems, Inc.*, 558 F.3d 1368, 1378 (Fed. Cir. 2009) (upholding summary judgment for lack of written description because the patent’s specification “describe[d] only medical valves with spikes,” but certain claims also covered “valves that operate . . . without a spike”).

However, Beckman’s initial, D.I. 586-1, Ex. A, final, D.I. 586-1, Ex. B, and supplemental final, D.I. 586-1, Ex. C, invalidity contentions related to lack of written description were directed to particular claim terms, *see, e.g.*, D.I. 586-1, Ex. B at 12, 16 & Ex. C at 12, 15. Beckman’s supplemental final invalidity contentions mention the BFMM term, *see, e.g.*, D.I. 577-1, Ex. 3, App’x B at 23, 29, 31, 34 (noting the BFMM term in a table of prior art disclosures), and the “plurality of detectors” term, D.I. 577-1, Ex. 3, App’x B at 2, 15, 22, 24, 28–30, 33 & App’x C at 2, 15, 29, 30, 39, 40 (same as BFMM term), as to other invalidity defenses, but not as to Beckman’s written description defense, *but see* D.I. 577-1, Ex. 3, App’x B at 3, 23 & App’x C at 3, 30 (reciting a claim that includes the BFMM term in a discussion of § 112 as to a different claim term). Beckman, itself, highlights invalidity contentions that relate to specific claim terms other than the “plurality of detectors” and the BFMM terms. *See, e.g.*, D.I. 586-1, Ex. A at 9, 11. Further, as the passages Beckman highlights demonstrate, Beckman’s expert discussed the lack of written description as to specific claim terms, but not as to the “plurality of detectors” or the BFMM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.